Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tevogen Bio Holdings Inc. - Common Stock (NQ: TVGN ) 0.4790 -0.0160 (-3.23%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tevogen Bio Holdings Inc. - Common Stock Tevogen Bio Secures $6 Million Series C Preferred Stock Investment August 22, 2024 From Tevogen Bio Inc Via GlobeNewswire CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares August 15, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health August 14, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities August 09, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback July 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian July 10, 2024 From Tevogen Bio Inc Via GlobeNewswire Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility July 08, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities June 26, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances June 25, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference June 18, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Set to Join Russell 3000® Index June 12, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts June 11, 2024 From Tevogen Bio Inc Via GlobeNewswire CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event June 07, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 June 06, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Reports First Quarter 2024 Financial Results May 29, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives May 16, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives May 10, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives May 01, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments April 26, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers April 11, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development April 03, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price March 28, 2024 From Tevogen Bio Inc Via GlobeNewswire Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant March 20, 2024 From Tevogen Bio Via Business Wire Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita March 05, 2024 From Tevogen Bio Via Business Wire Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI February 27, 2024 From Tevogen Bio Via Business Wire Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment February 21, 2024 From Tevogen Bio Via Business Wire Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market February 17, 2024 From Tevogen Bio Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.